الفهرس 
History & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
AIP is an uncommon form of chronic pancreatitis with a presumed autoimmune etiology and unique clinical, pathological, serological, and imaging features. There are two distinct subtypes, type 1 AIP is the pancreatic manifestation of IgG4-RD,while type 2 AIP. is a specific pancreatic disease. In 2011, ICDC for AIP (both types 1 and 2) were proposed. This ICDC were developed after review of previous criteria, including JPS (2002, 2006), HISORt (2006, 2009), Korean (2007), Asian (2008), Mannheim (2009), and Italian (2003). The goals of the ICDC for AIP are to develop criteria that can be applied worldwide, taking into consideration marked differences in clinical practice patterns, to avoid misdiagnosis of pancreatic cancer as AIP and to safely diagnose AIP to avoid unnecessary major hepatobiliary and pancreatic surgery as it responds dramatically to corticosteroid therapy. Currently steroids are the only proven approach for inducing disease remission in AIP.